Darzalex
J&J confident in new products as Stelara faces biosimilar threat
Anika Sharma
In the third quarter of 2023, Johnson & Johnson (J&J) exceeded analyst expectations, solidifying its position as a pharma and ...
Darzalex Continues Rising Trend – J&J Boosts Projected Yearly Revenues by $1 Billion
SG Tylor
In 2017, Genmab CEO Jan van de Winkel envisioned that the multiple myeloma drug Darzalex, marketed by Johnson & Johnson, ...
